Atherogenic Index of Plasma (AIP): The Lipid Risk a Normal LDL-C Can Miss

What the AIP score actually captures

AIP is the base-10 logarithm of the ratio of triglycerides to HDL cholesterol, with both values expressed in molar units (mmol/L): AIP = log₁₀(TG ÷ HDL-C). It compares the triglyceride load in your blood to the level of HDL, the lipoprotein involved in cholesterol transport and clearance. Higher AIP generally signals a lipoprotein pattern linked to atherosclerosis risk — more triglyceride-rich particles and less HDL support; lower AIP points toward a more favorable lipid environment. If your results are in mg/dL, unit conversion is required before calculation. The index was introduced by Dobiásová and Frohlich in 2001 (Clin Chem) as a composite marker of atherogenic dyslipidemia, and multiple cohort studies since have associated higher AIP with elevated cardiovascular event risk and metabolic conditions including type 2 diabetes and fatty liver. AIP is not a diagnosis — it is a signal to interpret alongside the rest of your clinical picture.

Why triglycerides and HDL only tell the story together

When the liver overproduces VLDL — triglyceride-rich particles — a specific exchange mechanism is set in motion. Cholesteryl ester transfer protein (CETP) swaps triglycerides from VLDL into both LDL and HDL particles in return for cholesteryl esters. The result is twofold: LDL particles become smaller and denser, a form more readily retained in arterial walls, and HDL particles become triglyceride-enriched and are catabolized faster, reducing their time in circulation. This is the biochemical core of atherogenic dyslipidemia — a pattern common in insulin resistance and metabolic syndrome — and it is precisely what the TG-to-HDL-C ratio is positioned to expose.

LDL-C alone misses this story because it reflects cholesterol mass, not particle character or HDL functionality. A person can carry a normal LDL-C while simultaneously running high VLDL output, accelerated HDL catabolism, and a dense-LDL shift — all captured in a rising AIP. That is why the two inputs only become informative when considered together: triglycerides reflect the upstream VLDL burden, and HDL-C reflects the downstream clearance capacity that CETP activity is simultaneously eroding.

The AIP formula, worked through step by step

The formula is:

AIP = log₁₀(Triglycerides [mmol/L] ÷ HDL-C [mmol/L])

Both inputs must be in millimoles per litre. If your lab reports in mg/dL, convert before calculating:

• TG (mg/dL) ÷ 88.57 = TG (mmol/L)
• HDL-C (mg/dL) ÷ 38.67 = HDL-C (mmol/L)

Fasting requirement: both inputs — especially triglycerides — must come from a fasting draw (8–12 hours). Fed-state triglycerides invalidate the score.

Worked example: A reader with fasting TG of 1.8 mmol/L and HDL-C of 1.2 mmol/L calculates: AIP = log₁₀(1.8 ÷ 1.2) = log₁₀(1.5) ≈ 0.18. That result sits in the intermediate-risk zone by the widely cited Dobiásová cutoffs, warranting attention alongside ApoB and non-HDL cholesterol.

Where your AIP score lands on the scale

AIP does not carry a single universal reference range — cutoffs can vary by population, sex, and method. The interpretive bands most widely cited from Dobiásová and Frohlich are:

• Below 0.11 — favorable; associated with lower atherogenic particle burden in population studies
• 0.11 to 0.21 — intermediate; warrants monitoring alongside companion markers such as ApoB and non-HDL cholesterol
• Above 0.21 — higher risk; consistent with atherogenic dyslipidemia, particularly when insulin resistance markers are also elevated

A unit-conversion caveat applies: if either input was not converted from mg/dL to mmol/L before the log₁₀ step, the resulting number will be meaningless — verify the units your lab uses before interpreting any score.

Context shapes interpretation. AIP tends to run higher in men than women, often rises with central adiposity, and may shift across menopause or with endocrine conditions such as hypothyroidism or PCOS. Because AIP is a derived metric, small assay differences in triglyceride or HDL-C measurement — for example, direct versus precipitation HDL-C methods — can nudge the value slightly. Treat your result as a conversation starter, not a verdict, and look for consistency across repeated measures rather than acting on a single data point.

What moves the AIP score in real life

Hepatic VLDL output and insulin resistance

The liver packages excess energy — particularly from refined carbohydrates and fructose — into VLDL particles. When glucose and fructose loads arrive rapidly and repeatedly, hepatic triglyceride synthesis accelerates and VLDL secretion rises, pushing the TG numerator of AIP upward. Insulin resistance compounds this: impaired insulin signalling reduces the liver's ability to suppress VLDL output, so the two processes reinforce each other. Conditions that drive insulin resistance — central adiposity, fatty liver, PCOS — therefore tend to move AIP higher through this mechanism.

Lipoprotein lipase and physical activity

Muscle contraction upregulates lipoprotein lipase (LPL) activity on capillary walls, pulling fatty acids out of circulating triglyceride-rich particles and into muscle for oxidation. This effect appears within hours of activity and is the direct mechanism by which exercise clears the TG numerator. Over weeks, consistent aerobic and resistance training improves insulin sensitivity and remodels lipoprotein profiles toward lower triglycerides and higher HDL — the combination that moves AIP in a favorable direction. HDL-C is the slower-moving of the two inputs; meaningful HDL rises with training typically take 4–8 weeks of consistent effort, which is why that component tends to be the rate-limiting factor in AIP improvement.

Sleep and circadian disruption

Sleep loss shifts hormones toward insulin resistance and raises sympathetic tone. The liver responds by increasing VLDL output, elevating the triglyceride numerator. Cortisol-driven stress states produce a similar effect, particularly when paired with late-night eating that misaligns nutrient timing with circadian liver rhythms. Shift work and jet lag can temporarily distort triglyceride handling through the same pathway.

Omega-3 fatty acids

Marine omega-3s (EPA and DHA) reduce hepatic VLDL production and enhance triglyceride clearance via hepatic pathways, which is why they consistently lower triglycerides in clinical trials. This acts directly on the TG numerator. Soluble fibers such as beta-glucan and psyllium slow carbohydrate absorption and dampen post-prandial triglyceride peaks through a complementary mechanism.

Medications and conditions

Thiazide diuretics, some beta-blockers, certain retinoids, and oral estrogens can raise triglycerides in susceptible individuals. Hypothyroidism, kidney disease, and fatty liver elevate triglycerides through impaired clearance or excess hepatic output. Pregnancy naturally raises triglycerides, especially in the third trimester. On the other side, fibrates and high-dose omega-3 therapies lower triglycerides through LPL activation and reduced VLDL synthesis respectively, and therapies that improve insulin sensitivity tend to reduce hepatic triglyceride output. Genetic lipid disorders can complicate the picture and may require specialist interpretation.

The panel that contextualizes the AIP score

• Triglycerides — the numerator input; rising triglycerides drive AIP up and reflect VLDL overproduction from the liver.
• HDL cholesterol — the denominator input; a low HDL-C is often the slower-moving component that limits AIP improvement cadence.
• Apolipoprotein B (ApoB) — counts all atherogenic particles; AIP and ApoB can diverge — high AIP with normal ApoB versus normal AIP with high ApoB tell different risk stories.
• Non-HDL cholesterol — approximates total ApoB-containing cholesterol; when AIP is high and non-HDL is elevated, triglyceride-rich remnant risk is compounded.
• hs-CRP — adds vascular inflammation context; elevated AIP with high hs-CRP reflects both atherogenic dyslipidemia and active vessel-wall stress.

When to retest AIP after a change

The two inputs move at different speeds. Triglycerides are fast-moving — they can shift meaningfully within days to weeks in response to dietary changes, alcohol reduction, or a new exercise habit. HDL-C is the slower component: consistent aerobic training typically produces detectable HDL-C rises over 4–8 weeks. Because AIP reflects both, the retest window should be paced to the slower input.

A 6–8 week retest is the standard interval — this is the point at which HDL-C changes become detectable and a directional read on AIP is meaningful. If you are monitoring a lipid-lowering intervention such as a fibrate or high-dose omega-3 therapy, a 12-week retest is acceptable and gives a fuller picture of the intervention's effect on both inputs.

Both inputs must be drawn fasting (8–12 hours) at every retest. For the most comparable results, use the same laboratory and the same morning fasted draw time — triglyceride assays are generally consistent across labs, but HDL-C methods (direct versus precipitation) can vary slightly and introduce apparent shifts that are methodological rather than biological.

When AIP findings deserve a clinician conversation

AIP is most useful as an early signal — a prompt to look more carefully before risk becomes established. Bring your results to a clinician if AIP is persistently above 0.21 across two or more fasting draws, particularly when accompanied by elevated non-HDL cholesterol, high ApoB, or markers of insulin resistance such as elevated fasting glucose or central adiposity. A single elevated reading during acute illness, after a period of poor sleep, or following significant dietary change is worth noting but not acting on in isolation.

AIP that is unexpectedly low also warrants context: very low triglycerides can reflect hyperthyroidism, malabsorption, or undernutrition, and very high HDL is not always functional. If the pattern does not fit the clinical picture, a clinician may check ApoB, consider remnant cholesterol, and screen for thyroid or liver issues to interpret the score safely.

Testing turns vague worry into actionable signal. AIP adds a metabolic layer to your lipid panel that can flag risk alongside LDL-C alone, especially when insulin resistance is in the mix. Trending it over time — aligned with how you feel, how you train, and what you change — turns a single number into a feedback loop. A comprehensive panel that includes AIP alongside ApoB, non-HDL cholesterol, hs-CRP, liver enzymes, and glucose control shows the full lipoprotein picture at once, helping you and your clinician translate trends into personalized decisions grounded in evidence. That is the approach behind Superpower — if you want to understand the thinking, the manifesto lays it out.